Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06200181 · ClinicalTrials.gov registry record · Phase 3
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
A Phase 3 study of Misuse, Opioid, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT06200181: Recruiting Phase 3 study of Misuse, Opioid, sponsored by M.D. Anderson Cancer Center.
NCT06200181 is a Phase 3 study of Misuse, Opioid that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 87 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06200181, a Phase 3 study of Misuse, Opioid, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Olanzapine
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 3 |
What NCT06200181 shows while recruiting
NCT06200181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Misuse, Opioid appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06200181 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06200181 about?
NCT06200181 is a clinical study titled "Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial". To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.
What is the current status of trial NCT06200181?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2024-04-02. Estimated completion is 2026-11-01.
What conditions does trial NCT06200181 study?
This clinical trial studies the following conditions: Misuse, Opioid.
What interventions are being tested in trial NCT06200181?
The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT06200181?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06200181 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06200181's enrollment target sits among peer trials
87 1743rd of 2000 higher than 256 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI